FDA Bestows SPA for Achaogen Antibiotic Trial
By Catherine Shaffer
Staff Writer
Staff Writer
Monday, September 23, 2013
A Phase III trial of Achaogen Inc.’s plazomicin for serious multidrug-resistant gram-negative bacterial infections will be carried out through a special protocol assessment (SPA) under a new agreement with the FDA. The trial will assess safety and efficacy of the drug compared with colistin in patients with bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant Enterobacteriaceae.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.